International Journal of Infertility & Fetal Medicine

Register      Login

VOLUME 6 , ISSUE 2 ( May-August, 2015 ) > List of Articles


Role of Anti-Müllerian Hormone in Gynecology: A Review of Literature

Naina Kumar, Amit Kant Singh

Citation Information : Kumar N, Singh AK. Role of Anti-Müllerian Hormone in Gynecology: A Review of Literature. Int J Infertil Fetal Med 2015; 6 (2):51-61.

DOI: 10.5005/jp-journals-10016-1102

License: CC BY-NC 4.0

Published Online: 01-04-2012

Copyright Statement:  Copyright © 2015; The Author(s).



The literature regarding AMH was searched from various English language journals and published peer-reviewed articles on Pubmed, MEDLINE and Google Scholar till 2014.

How to cite this article

Kumar N, Singh AK. Role of Antimüllerian Hormone in Gynecology: A Review of Literature. Int J Infertil Fetal Med 2015;6(2):51-61.

PDF Share
  1. Isolation of the bovine and human genes for MIS and expression of the human gene in animal cells. Cell 1986;45(5):685-698.
  2. Mapping of the gene for antimüllerian hormone to the short arm of human chromosome 19. Cytogenet Cell Genet 1987;44(1):2-6.
  3. Anti-Müllerian hormone recruits BMPR-IA in immature granulosa cells. PLoS ONE, Public Library of Science 2013; 8(11):e81551.
  4. Anti-müllerian hormone in female reproduction: is measurement of circulating AMH a useful tool? Clin Endocrinol 2006;64(6):603-610.
  5. Smad transcription factors. Genes Dev 2005;19(23):2783-2810.
  6. Serum anti-Müllerian hormone as a predictive marker of polycystic ovarian syndrome. Int J General Med 2011;4(2):759-763.
  7. Endocrine Physiology. 3rd ed. New York: McGraw- Hill Medical Companies 2010;215-253.
  8. Anti-Müllerian hormone and ovarian dysfunction. Trends Endocrinol Metab 2008;19(9):340-347.
  9. Expression of Anti-Müllerian hormone during normal and pathological gonadal development: association with differentiation of sertoli and granulosa cells. J Clin Endocrinol Metab 1999;84(10):3836-3844.
  10. Anti-Müllerian hormone inhibits initiation of primordial follicle growth in the mouse ovary. Endocrinol 2002;143(3):1076-1084.
  11. Control of primordial follicle recruitment by Anti-Müllerian hormone in the mouse ovary. Endocrinol 1999;140(12):5789-5796.
  12. Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 2004;10(2):77-83.
  13. Which follicles make the most Anti-Müllerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection. Mol Hum Reprod 2013;19(8):519-527.
  14. Anti-Müllerian hormone levels and antral follicle count in women enrolled in in vitro fertilization cycles: relationship to lifestyle factors, chronological age and reproductive history. Gynecol Endocrinol 2007;23(8):486-493.
  15. Comparison of inter- and intracycle variability of Anti-Müllerian hormone and antral follicle counts. Hum Reprod 2010;25(1):221-227.
  16. Serum Anti-Müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod 2003;18(2): 323-327.
  17. Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 2004;89(1):318-323.
  18. Anti-Müllerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril 2002;77(2):357-362.
  19. Serum Anti-Müllerian hormone levels: a novel measure of ovarian reserve. Hum Reprod 2002;17(12): 3065-3071.
  20. Müllerian inhibiting substance in humans: normal levels from infancy to adulthood. J Clin Endocrinol Metab 1996;81(2):571-576.
  21. Serum Müllerian inhibiting substance levels during normal menstrual cycles. Fertil Steril 2000;73(4):859-861.
  22. High reproducibility of serum Anti-Müllerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status. Human Reprod 2005;20(4):923-927.
  23. Clinical uses of Anti-Müllerian hormone assays: pitfalls and promises. Fertil Steril 2009;91(1):226-230.
  24. Early follicular serum Müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril 2002;77(3):468-471.
  25. Anti-Müllerian hormone as a predictive marker in assisted reproductive technology. Hum Reprod Update 2010;16(2):113-130.
  26. A validated model of serum Anti-Müllerian hormone from conception to menopause. Vitzthum VJ, editor. PLoS ONE 2011;6(7):e22024.
  27. External validation of nomogram for the decline in serum Anti-Müllerian hormone in women: a population study of 15,834 infertility patients. Reprod Biomed Online 2011;23(2):204-206.
  28. Human ovarian reserve from conception to the menopause. PloS One 2010;5(1):e8772.
  29. A new model of reproductive aging: the decline in ovarian non-growing follicle number from birth to menopause. Human Reprod 2008;23(3):699-708.
  30. Serum Anti-Müllerian hormone levels best resect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril 2005;83(4):979-987.
  31. Serum levels of Anti-Müllerian hormone as a marker of ovarian function in 926 healthy females from birth to adulthood and in 172 Turner syndrome patients. J Clin Endocrinol Metab 2010;95(11):5003-5010.
  32. The concordance between serum Anti-Müllerian hormone and testosterone concentrations depends on duration of hCG stimulation in boys undergoing investigation of gonadal function. Clin Endocrinol 2010;72(6):814-819.
  35. The physiology and clinical utility of anti-Müllerian hormone in women. Hum Reprod Update 2014;20(3):370-385.
  36. Anti-Müllerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinol 2001;142(11):4891-4899.
  37. Actions of Anti-Müllerian hormone on the ovarian transcriptome to inhibit primordial to primary follicle transition. Reproduction 2007;134(2): 209-221.
  38. Increased oocyte degeneration and follicular atresia during the estrous cycle in Anti-Müllerian hormone null mice. Endocrinol 2007;148(5):2301-2308.
  39. Regulation of ovarian function: the role of Anti-Müllerian hormone. Reproduction 2002;124(5):601-609.
  40. Evidence for a role for Anti-Müllerian hormone in the suppression of follicle activation in mouse ovaries and bovine ovarian cortex grafted beneath the chick chorioallantoic membrane. Mol Reprod Dev 2005;71(4):480-488.
  41. Anti-Müllerian hormone inhibits initiation of growth of human primordial ovarian follicles in vitro. Hum Reprod 2006;21(9):2223-2227.
  42. Anti-Müllerian hormone initiates growth of human primordial follicles in vitro. Mol Cell Endocrinol 2005;234(1-2):87-93.
  43. Anti-Müllerian hormone (AMH) downregulation in late antral stages is impaired in PCOS patients. A study in normo-ovulatory and PCOS patients undergoing in vitro maturation (IVM) treatments. Gynecol Endocrinol 2013;29(7):651-656.
  44. Concentrations of AMH and inhibin-B in relation to follicular diameter in normal human small antral follicles. Hum Reprod 2010;25(5):1282-1287.
  45. Anti-Müllerian Hormone level and expression in mural and cumulus cells in relation to age. J Ovarian Res 2014;7:113.
  46. Differential regulation of ovarian Anti-Müllerian hormone by estradiol through α- and β-estrogen receptors. J Clin Endocrinol Metab 2012;97(9):E1649-1657.
  47. Purification of testicular Anti-Müllerian hormone allowing direct visualization of the pure glycoprotein and determination of yield and purification factor. Mol Cell Endocrinol 1984;34(1):23-29.
  48. Proteolytic processing of müllerian inhibiting substance produces a transforming growth factorbeta- like fragment. J Biol Chem 1988;263(55):18961-18964.
  49. Bioactivation of Müllerian inhibiting substance during gonadal development by a kex2/subtilisin-like endoprotease. Proc Natl Acad Sci USA 1996;93(15):7711-7716.
  50. Mullerian inhibiting substance: a gonadal hormone with multiple functions. Endocrine Reviews 1993;14(2):152-164.
  51. Müllerian inhibiting substance requires its N-terminal domain for maintenance of biological activity, a novel finding within the transforming growth factor-beta superfamily. Mol Endocrinol 1993;7(2):247-257.
  52. Mutations of the Anti-Müllerian hormone gene in patients with persistent mullerian duct syndrome: biosynthesis, secretion, and processing of the abnormal proteins and analysis using a three-dimensional model. Mol Endocrinol 2004;18(3):708-721.
  53. Anti-Müllerian hormone: a new marker for ovarian function. Reproduction 2006;131(1):1-9.
  54. Serum levels of Müllerian inhibiting substance in boys from birth to 18 years, as determined by enzyme immunoassay. J Clin Endocrinol Metab 1990;70(1):11-15.
  55. An immunoassay to detect human mullerian inhibiting substance in males and females during normal development. J Clin Endocrinol Metab 1990;70(1):16-22.
  56. An enzyme linked immunoassay for Anti-Müllerian hormone: a new tool for the evaluation of testicular function in infants and children. J Clin Endocrinol Metab 1990;70(1):23-27.
  57. Serum Anti-Müllerian hormone levels reflect the size of the primordial follicle pool in mice. Endocrinology 2006;147(7):3228-3234.
  58. Anti-Müllerian hormone: a unique biochemical marker of gonadal development and fertility in humans. Biochem Med 2011;21(3):219-230.
  59. Development of a second generation Anti-Müllerian hormone (AMH) ELISA. J Immunol Methods 2010;362(1-2):51-59.
  60. A multicentre evaluation of the new beckman coulter Anti-Müllerian hormone immunoassay (AMH Gen II). Ann Clin Biochem 2011;48(pt 4):370-373.
  61. Development of a sensitive enzyme immunoassay for Anti-Müllerian hormone and the evaluation of potential clinical applications in males and females. Clin Endocrinol (Oxf) 2005;63(3):267-273.
  62. Age-related normograms of serum Antimüllerian hormone levels in a population of infertile women: a multicenter study. Fertil Steril 2011;95(7):2359-2363, 2363 e1.
  63. Age-specific nomogram for the decline in antral follicle count throughout the reproductive period. Fertil Steril 2011;95(2):684-688.
  64. Anti-Müllerian hormone-based prediction model for a live birth in assisted reproduction. Reprod Biomed Online 2011;22(4):341-349.
  65. Variations in serum Müllerian inhibiting substance between white, black, and Hispanic women. Fertil Steril 2009;92(5):1674-1678.
  66. Genetic variants and environmental factors associated with hormonal markers of ovarian reserve in Caucasian and African American women. Hum Reprod 2012;27(2):594-608.
  67. Anti-Müllerian hormone in the management of infertility. Middle East Fertility Society J, 2014;19(1):1-7.
  68. Association of anti-Müllerian hormone levels with obesity in late reproductive-age women. Fertil Steril 2007;87(1):101-106.
  69. Anti-müllerian hormone and obesity: insights in oral contraceptive users. Contraception 2010;81(3):245-248.
  70. Effect of obesity on parameters of ovarian reserve in premenopausal women. J Obstet Gynaecol Can 2010;32(7): 687-690.
  71. Is the plasma anti-Müllerian hormone level associated with body weight and metabolic, and hormonal disturbances in women with and without polycystic ovary syndrome? Eur J Obstet Gynecol Reprod Biol 2011;158(2): 254-259.
  72. Development of a nomogram based on markers of ovarian reserve for the individualisation of the follicle-stimulating hormone starting dose in in vitro fertilisation cycles. BJOG 2012;119(10):1171-1179.
  73. Normal serum anti-Müllerian hormone levels in the general female population and the relationship with reproductive history. Eur J Obstet Gynecol Reprod Biol 2012;163(2):180-184.
  74. Intra-cycle fluctuations of anti-Müllerian hormone in normal women with a regular cycle: a re-analysis. Reprod Biomed Online 2012;24(6):664-669.
  75. The impact of smoking on Anti-Müllerian hormone levels in women aged 38 to 50 years. Menopause 2010;17(3):571-576.
  76. Ovarian reserve and in vitro fertilization cycles outcome according to women smoking status and stimulation regimen. Arch Gynecol Obstet 2012;285(4):1177-1182.
  77. Smoking and AMH levels in women with normal reproductive history. Arch Gynecol Obstet 2010;282(2):215-219.
  78. Effect of cigarette smoking upon reproductive hormones in women of reproductive age: a retrospective analysis. Reprod Biomed Online 2010;20(6): 861-865.
  79. The clinical significance of Anti-Müllerian hormone evaluation in gynecological endocrinology. Hormones 2011;10(2):95-103.
  80. Serum anti-Müllerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic steroids. Fertil Steril 2008;90(2): 395-400.
  81. The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical byperaudro genemin. Gynecol Endocrinol 2010;27(8):587-592.
  82. Antimullerian hormone and pituitary gland activity after prolonged down-regulation with goserelin acetate. Fertil Steril 2006;86(5):1515-1517.
  83. Stable serum levels of Anti-Müllerian hormone during the menstrual cycle: a prospective study in normoovulatory women. Hum Reprod 2007;22(7):1837-1840.
  84. Variations in serum mullerian inhibiting substance between white, black, and hispanic women. Fertil Steril 2009;92(5):1674-1678.
  85. Defining ovarian reserve to better understand ovarian aging. Reproduct Bio Endocrinol: RB&E 2011;9:23.
  86. Correlation of ovarian reserve tests with histologically determined primordial follicle number. Fertil Steril 2011;95(1):170-175.
  87. Gonadotropin releasing hormone antagonists suppress aromatase and anti- Müllerian hormone expression in human granulosa cells. Fertil Steril 2010;94(5):1832-1839.
  88. Anti-Müllerian hormone in premenopausal women and after spontaneous or surgically induced menopause. J Soc Gynecol Investig 2005;12(7):545-548.
  89. Anti- Müllerian hormone concentrations in maternal serum during pregnancy. Hum Reprod 2005;20(6):1569-1572.
  90. Serum Anti- Müllerian hormone throughout the human menstrual cycle. Hum Reprod 2006;21(12):3103-3107.
  91. Serum anti-Müllerian hormone levels and fillicular cohort characteristics after pituitary suppression in the late luteal phase with oral contraceptive pills. Hum Reprod 2007;22(12):3192-3196.
  92. Active smoking compromises IVF outcome and affects ovarian reserve. Reprod Biomed Online 2008;16(1):96-102.
  93. Serum Anti-Müllerian hormone levels in women with secondary amenorrhea. Fertil Steril 2006;85(5):1547-1549.
  94. Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum Reprod 2007;22(3):766-771.
  95. ESHRE special interest group for reproductive endocrinology– amh round table. Anti-Müllerian hormone (AMH): what do we still need to know? Hum Reprod 2009;24(9): 2264-2275.
  96. Anti-Müllerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. J Clin Endocrinol Metab 2008;93(9):3478-3483.
  97. Elevated serum level of AMH in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab 2003;88(12):5957-5962.
  98. Serum Anti-Müllerian hormone concentrations are elevated in oligomenorrheic girls without evidence of hyperandrogenism. J Clin Endocr Metab 2010;95(4): 1786-1792.
  99. Serum Anti-Müllerian hormone and inhibin B concentrations are not useful predictors of ovarian response during ovulation induction treatment with recombinant follicle-stimulating hormone in women with polycystic ovary syndrome. Fertil Steril. Fertil Steril 2011;96(2):459-463.
  100. Granulosa cell production of anti-Müllerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab 2007;92(1):240-245.
  101. Anti- Müllerian hormone is increased in follicular fluid from unstimulated ovaries in women with polycystic ovary syndrome. Hum Reprod 2008;23(9):2122-2126.
  102. Anti-Müllerian hormone and polycystic ovary syndrome: a mountain too high? Reproduction 2010 May;139(5):825-833.
  103. Anti-Müllerian hormone, its receptor, FSH receptor, and androgen receptor genes are overexpressed by granulosa cells from stimulated follicles in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2008;93(11):4456-4461.
  104. Serum Anti-Müllerian hormone levels during controlled ovarian hyperstimulation in women with polycystic ovaries with and without hyperandrogenism. Hum Reprod 2005;20(7):1814-1819.
  105. Anti-Müllerian hormone concentrations in androgen-suppressed women with polycystic ovary syndrome. Hum Reprod 2009;24(7):1732-1738.
  106. Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. J Clin Endocrinol Metab 1994;79(4):1158-1165.
  107. Clinical implications of hyperinsulinaemia in women. Clin Endocrinol 1993;39(6):623-632.
  108. The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovarian syndrome. J Clin Endocrinol Metab 1988;66(1):131-139.
  109. Mullerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics. Fertil Steril 2004;82(4):970-972.
  110. Modulation by insulin of follicle-stimulating hormone and luteinizing hormone actions in human granulosa cells of normal and polycystic ovaries. J Clin Endocrinol Metab 1996;81(1):302-309.
  111. Acute effects of metformin therapy include improvement of insulin resistance and ovarian morphology. Fertil Steril 2007;87(4):870-875.
  112. Developmental programming: impact of excess prenatal testosterone on intrauterine fetal endocrine milieu and growth in sheep. Biol Reprod 2011;84(1): 87-96.
  113. Anti-Müllerian hormone reduces follicle sensitivity to follicle stimulating hormone in human granulosa cells. Fertil Steril 2011;96(5):1246-1251e1.
  114. Loss of LH-induced down-regulation of Anti- Müllerian hormone receptor expression may contribute to anovulation in women with polycystic ovary syndrome. Hum Reprod 2013;28(3):762-769.
  115. Anti-Müllerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Physiol Endocrinol Metab 2009 Feb;296(2):E238-E243.
  116. Polycystic ovaries at ultrasound: normal variant or silent polycystic ovary syndrome? Ultrasound Obstet Gynecol 2012;40(2):223-229.
  117. Serum AMH levels remain high until late reproductive age and decrease during metformin treatment in women with polycystic ovary syndrome. Hum Reprod 2005;20(7):1820-1826.
  118. Serum Müllerian inhibiting substance levels in adolescent girls with normal menstrual cycles or with polycystic ovary syndrome. Fertil Steril 2005;84(4):938-944.
  119. Increased Anti-Müllerian hormone serum concentrations in prepubertal daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91(8):3105-3109.
  120. Adrenal hyperandrogenism is induced by fetal androgen excess in a rhesus monkey model of polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90(12):6630-6637.
  121. Clinical review: Identifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92(3):787-796.
  122. Serum LH levels are markedly increased and significantly correlated with Delta 4-androstendione levels in lean women with polycystic ovary syndrome. Fertil Steril 2005;84(2):538-540.
  123. Anti-Müllerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation. Human Reprod 2004;19(12):2738-2741.
  124. Phenotypic expression, body mass index and insulin resistance in relation to LH levels in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2011;156(2):181-185.
  125. Serum Anti-Müllerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91(3):941-945.
  126. The role of Anti-Müllerian hormone in assisted reproduction. Middle East Fertility Society J 2012;17(3):157-160.
  127. The role of Anti-Müllerian hormone assessment in assisted reproductive technology outcome. Curr Opin Obstet Gynecol 2010;22(3):193-201.
  128. Anti-Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception. Hum Reprod 2009;24(4):867-875.
  129. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update 2006;12(6):685-718.
  130. Anti-Müllerian hormone concentrations in the follicular fluid of the preovulatory follicle are predictive of the implantation potential of the ensuing embryo obtained by in vitro fertilization. J Clin Endocrinol Metab 2007;92(5):1796-1802.
  131. Anti-Müllerian hormone and inhibin B as predictors of pregnancy after treatment by in vitro fertilization/intracytoplasmic sperm injecton. Fertil Steril 2008;90(6):2203-2210.
  132. Why we may abandon basal folliclestimulating hormone testing: a sea change in determining ovarian reserve using antimüllerian hormone. Fertil Steril 2013;99(7):1825-1830.
  133. The correlation between follicular fluid antimullerian hormone levels and fertilization and embryo quality in art cycles. Int J Infert Fetal Med 2012;3(3):83-86.
  134. Anti-Müllerian hormone substance from follicular fluid is positively associated with success in oocyte fertilization during in vitro fertilization. Fertil Steril 2008;89(3):586-591.
  135. Follicular fluid levels of Anti-Müllerian hormone as a predictor of oocyte maturation, fertilization rate, and embryonic development in patients with polycystic ovary syndrome. Fertil Steril 2010;93(7):2299-2302.
  136. Anti-Müllerian hormone is specific marker of sertoliand granulose-cell origin in gonadal tumors. Hum Pathol 2000;31(10):1202-1208.
  137. Detection of minimal levels of Anti-Müllerian hormone during follow-up of patients with ovarian granulosa cell tumor by means of a highly sensitive enzyme-linked immunosorbent assay. J Clin Endocrinol Metab 2000;85(2):540-544.
  138. The role of inhibins B and Anti-Müllerian hormone for diagnosis and follow-up of granulosa cell tumors. Int J Gynecol Cancer 2009;19(5):847-855.
  139. Serum Müllerian inhibiting substance/Anti-Müllerian hormone levels in patients with adult granulosa cell tumors directly correlate with aggregate tumor mass as determined by pathology or radiology. Gynecol Oncol 2009;114(1):57-60.
  140. Relationships between FSH, inhibin B, Anti-Müllerian hormone, and testosterone during long-term treatment with the GnRH-agonist histrelin in patients with prostate cancer. Eur J Endocrinol 2010;162(1):177-181.
  141. Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by Anti-Müllerian hormone, inhibin B and ovarian ultrasound. Hum Reprod 2003;18(11):2368-2374.
  142. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertil Steril 2010;94(2):638-644.
  143. Anti- Müllerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood. J Clin Endocrinol Metab 2007;92(10):3869-3874.
  144. Ovarian function after removal of an entire ovary for cryopreservation of pieces of cortex prior to gonadotoxic treatment: a follow-up study. Hum Reprod 2008;23(11):2475-2483.
  145. Assessment of ovarian reserve in adult childhood cancer survivors using Anti-Müllerian hormone. Hum Reprod 2009;24(4):982-990.
  146. Impact of cancer therapies on ovarian reserve. Fertil Steril 2012;97(1):134-140e1.
  147. Anti-Müllerian hormone follow-up in young women treated by chemotherapy for lymphoma: preliminary results. Reprod Biomed online 2010;20(2):280-285.
  148. Anti-Müllerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: a prospective study. J Clin Endocrinol Metab 2012;97(6):2059-2067.
  149. Surgical excision of endometriomas and ovarian reserve: a systematic review on serum anti-Mullerian hormone level modifications. Fertil Steril 2012;98(6):1531-1538.
  150. In women with endometriosis Anti-Müllerian hormone levels are decreased only in those with previous endometrioma surgery. Hum Reprod 2012;27(11):3294-3303.
  151. Ovarian and adipose tissue dysfunction in polycystic ovary syndrome: report of the 4th special scientific meeting of the Androgen Excess and PCOS Society. Fertil Steril 2010;94(2):690-693.
  152. Executive summary of the stages of reproductive aging workshop +10: addressing the unfinished agenda of staging reproductive aging. Fertil Steril 2012;97(4):843-851.
  153. Anti-Müllerian hormone is a more accurate predictor of individual time to menopause than mother's age at menopause. Hum Reprod 2014;29(3): 584-591.
  154. Role of antimullerian hormone as a biomarker of the menopausal transition. Menopause 2013;20(2):218-222.
  155. The relationship between Anti-Müllerian hormone in women receiving fertility assessments and age at menopause in subfertile women: evidence from large population studies. J Clin Endocrinol Metab 2013;98(5):1946-1953.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.